Digestive Diseases and Sciences最新文献_第7页

IBS and IBD-One Letter, Much Pain, Few Treatments.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-14 DOI: 10.1007/s10620-025-08892-5

Jaime E Scott, Sasha Taleban

引用次数: 0

An Unusual Case of Gastric Mucosal Erosions.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-14 DOI: 10.1007/s10620-025-08894-3

Yingxin Chen, Kun Ma, Yange Zhao, Tianyuan Yuan, Shaoxuan Wang

引用次数: 0

Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08876-5

Jaakko Rautakorpi, Sara Kolehmainen, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Taina Sipponen, Kimmo Salminen

{"title":"Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.","authors":"Jaakko Rautakorpi, Sara Kolehmainen, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Taina Sipponen, Kimmo Salminen","doi":"10.1007/s10620-025-08876-5","DOIUrl":"https://doi.org/10.1007/s10620-025-08876-5","url":null,"abstract":"Background: Recent studies suggest that subcutaneous infliximab is effective and safe for treating patients with inflammatory bowel disease. Real-world studies with larger cohorts are needed to confirm the efficacy of subcutaneous treatment.Aims: The aim was to assess real-world treatment persistence, clinical outcomes, infliximab concentrations, and treatment safety after switching from intravenous to subcutaneous infliximab treatment with patients with inflammatory bowel disease.Methods: This retrospective register-based study included patients with inflammatory bowel disease who were in clinical remission and switched from intravenous infliximab maintenance therapy to subcutaneous infliximab in two tertiary centers.Results: A total of 274 patients (104 Crohn's disease and 170 ulcerative colitis) were included. After the switch, the treatment persistence at 12 months was 94.8% in patients with Crohn's disease and 88.8% in patients with ulcerative colitis. Only 11.3% (n = 31) of the patients discontinued the treatment during 79-week median follow-up. Compared to the baseline, no change occurred in clinical disease activity at the time points of 3, 6, and 12 months, based on the Harvey-Bradshaw Index or partial Mayo Score (p = 0.792 and p = 0.426, respectively). Infliximab median concentrations were higher (p < 0.0001) during subcutaneous treatment (16.75 µg/ml) compared to the intravenous treatment median trough levels before the switch (6.71 µg/ml). In total, 15.0% (n = 41) of the patients reported adverse events.Conclusion: Switching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective Video-Based Study Assessing Effect of Computer-Assisted Optical Diagnosis on Distinguishing Serrated, Hyperplastic, and Adenomatous Colorectal Polyps.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08879-2

Dong Hyun Kim, Sofie Fournier, Edgard Medawar, Roupen Djinbachian, Mahsa Taghiakbari, Alan Barkun, Douglas K Rex, Heiko Pohl, Yutaka Saito, Amrita Sethi, Philip Wai Yan Chiu, Roberta Maselli, Mathieu Pioche, Jeffrey Marks, Maher Al Khaldi, Katarzyna Pawlak, Herawaty Sebajang, Florence Benard, Roy Hajjar, Melissa Zarandi-Nowroozi, Frank Schwenter, Daniel von Renteln

{"title":"Prospective Video-Based Study Assessing Effect of Computer-Assisted Optical Diagnosis on Distinguishing Serrated, Hyperplastic, and Adenomatous Colorectal Polyps.","authors":"Dong Hyun Kim, Sofie Fournier, Edgard Medawar, Roupen Djinbachian, Mahsa Taghiakbari, Alan Barkun, Douglas K Rex, Heiko Pohl, Yutaka Saito, Amrita Sethi, Philip Wai Yan Chiu, Roberta Maselli, Mathieu Pioche, Jeffrey Marks, Maher Al Khaldi, Katarzyna Pawlak, Herawaty Sebajang, Florence Benard, Roy Hajjar, Melissa Zarandi-Nowroozi, Frank Schwenter, Daniel von Renteln","doi":"10.1007/s10620-025-08879-2","DOIUrl":"https://doi.org/10.1007/s10620-025-08879-2","url":null,"abstract":"Background/aim: The current computer-aided diagnosis (CADx) systems are not trained to recognize sessile-serrated lesions (SSL) and currently classify SSL incorrectly either as hyperplastic or adenomatous. We aimed to assess the effect of current untrained CADx systems on diagnostic accuracy of SSL recognition among a diverse group of endoscopists.Methods: 17 endoscopists reviewed the same video and image series of 115 polyps [33% SL, 33% Hyperplastic Polyps (HP), and 34% tubular adenoma (TA)]. Presentation of polyps (SSL, TA, HP) was randomized with 50% of the polyps being displayed with a CADx diagnosis, and other 50% without.Results: CADx identified 52.6% of SSL as HP and 47.4% as TA. CADx identified 68.4% of HP correctly and 82.1% of TA correctly. The accuracy of the endoscopists for SSL did not differ significantly when the CADx diagnosis was displayed compared to no CADx being displayed (64.1% vs 64.9%, p > 0.05). The diagnostic accuracy for HP and TA improved among endoscopists when a correct CADx diagnosis was displayed to the endoscopists compared to when no CADx information was displayed but worsened when the displayed CADx diagnosis was incorrect.Conclusion: Current CADx systems when displaying correct diagnostic outputs for HP or TA improve diagnostic accuracy of the endoscopists. CADx systems not trained for SSL recognition do not significantly affect SSL recognition among endoscopists even if an incorrect diagnostic output (TA or HP) is displayed.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of Acute Pancreatitis Hospitalizations with Obesity.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08880-9

Neelam Khetpal, Mohamad Sharbatji, Mohammad Maysara Asfari, Sarfraz Ahmad

{"title":"Outcomes of Acute Pancreatitis Hospitalizations with Obesity.","authors":"Neelam Khetpal, Mohamad Sharbatji, Mohammad Maysara Asfari, Sarfraz Ahmad","doi":"10.1007/s10620-025-08880-9","DOIUrl":"https://doi.org/10.1007/s10620-025-08880-9","url":null,"abstract":"Objective: Assessing the relationship of body mass index (BMI) on acute pancreatitis (AP) hospitalization in the United States (US).Methods: The National Inpatient Sample utilized to capture normal weight, overweight, and obese AP hospitalization in the US during 2020 based on BMI. Patients, hospitalization characteristics, and outcomes were compared.Results: In 2020, there were 53,000 (20%) obese, 3980 (2.6%) overweight, and 210,000 (77.4%) normal weight AP hospitalizations. All-cause inpatient mortality was similar for obese, and overweight compared to normal weight AP hospitalizations, respectively (0.65% vs 0.63% vs 0.6%). Furthermore, obese AP hospitalization had a higher chance of developing systemic [odds ratio (OR): 1.7, confidence interval (CI) (1.35-2.12)], and needing intubation or vasopressor requirement OR: 1.75, CI (1.14-2.68), compared to normal AP patients. However, overweight AP hospitalizations had similar chance of developing systemic OR: 1.1, CI (0.83-1.38) and local complication OR: 1.14, CI (0.88-1.5), needing intubation or vasopressor requirements OR: 1.27, CI (0.73-2.23) except use of jejunostomy tube was higher OR: 1.74, CI (1.1-2.75) compared to normal weight AP hospitalizations. The mean length-of-stay and mean total healthcare costs were higher among obese by 2.14 days (CI 0.9-3.37), p = 0.001 and by US$ 21,626, CI (4379-38,872), p = 0.014 compared to normal weight AP hospitalizations.Conclusions: Obese and overnight AP hospitalizations had similar inpatient mortality compared to normal weight hospitalizations. Obese AP hospitalizations have higher complications and healthcare utilization compared to normal weight hospitalizations.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver Biopsy - An Essential LiFT in the Diagnosis of Unexplained Liver Disease.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08900-8

Don C Rockey

引用次数: 0

Prevalence, Clinical Features, and Extraintestinal Manifestations in Patients with Familial Inflammatory Bowel Diseases.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08868-5

Christina Liava, Danai Chourmouzi, Emmanouil Sinakos, Theodoros Dimitroulas, Christina Navrozidou, Evangelos Akriviadis

{"title":"Prevalence, Clinical Features, and Extraintestinal Manifestations in Patients with Familial Inflammatory Bowel Diseases.","authors":"Christina Liava, Danai Chourmouzi, Emmanouil Sinakos, Theodoros Dimitroulas, Christina Navrozidou, Evangelos Akriviadis","doi":"10.1007/s10620-025-08868-5","DOIUrl":"https://doi.org/10.1007/s10620-025-08868-5","url":null,"abstract":"Background: A positive family history is considered the strongest recognizable risk factor for developing inflammatory bowel diseases (IBD) and is present in 8-12% of cases.Aims: To determine the prevalence of familial IBD and also to compare the clinical characteristics and extraintestinal manifestations between familial and sporadic cases.Methods: We conducted a cross-sectional study based on retrospectively-prospectively collected data from a cohort of IBD patients followed in daily clinical practice. Patients with biopsy-confirmed familial and sporadic IBD aged 16-90 years old were included in the study. A comprehensive questionnaire was used to collect data on each site visit. Logistic regression analysis and chi-squared test were used.Results: In total, 265 patients with IBD were included. 12.1% had a first-degree relative with IBD present (16.4% in Crohn's disease and 5.7% in the ulcerative colitis group, P < 0.05). Familial IBD patients were mainly females, were more frequently diagnosed with Crohn's disease and had a higher risk for hospitalization due to an IBD flare (P < 0.05), to undergo a surgical procedure (P < 0.001), to require treatment with biologic agents (P < 0.05), to develop perianal disease (P < 0.05), and extraintestinal manifestations (P < 0.05), mainly spine joint complications, erythema nodosum, and anterior uveitis.Conclusion: In this study, a positive family history of IBD was present in 16.4% of Crohn's disease and 5.7% of ulcerative colitis patients and was associated with a greater risk for hospitalization, surgical procedures, occurrence of perianal disease, need for treatment with biologic agents, and development of extraintestinal manifestations.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed Corticosteroid Treatment for Patients Requiring Hospitalization for Acute Inflammatory Bowel Disease Exacerbations Increases Length of Stay and Risk for Surgery in Crohn's Disease.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08907-1

Jaya Vasudevan, Bhuvana Mukkamala, Bani Dhother, Paul Guzik, Zhouwen David Tang, Linda A Feagins

{"title":"Delayed Corticosteroid Treatment for Patients Requiring Hospitalization for Acute Inflammatory Bowel Disease Exacerbations Increases Length of Stay and Risk for Surgery in Crohn's Disease.","authors":"Jaya Vasudevan, Bhuvana Mukkamala, Bani Dhother, Paul Guzik, Zhouwen David Tang, Linda A Feagins","doi":"10.1007/s10620-025-08907-1","DOIUrl":"https://doi.org/10.1007/s10620-025-08907-1","url":null,"abstract":"Background: While corticosteroids are not recommended for maintenance of remission in inflammatory bowel disease (IBD), they are quite effective for the induction of remission for both Crohn's disease (CD) and ulcerative colitis (UC). We aimed to evaluate if a delay in starting corticosteroids after presentation to the hospital for an acute IBD exacerbation increased the likelihood of poor outcomes.Methods: Retrospective cohort study of IBD-related hospitalizations from 7 area hospitals in Austin, Texas between 2015 and 2020. Patients were included if admitted for an IBD flare and received corticosteroids. CD with intra-abdominal abscesses were excluded. Primary outcomes were length of stay (LOS), ICU stay, IBD-related surgery, and mortality.Results: Of 478 inpatients, 311 (65%) received corticosteroids within 12 h of arrival. ICU stays (4.2% vs. 5.4%, p = 0.88, early vs. late corticosteroids) and inpatient mortality (1.0% vs. 1.8%, p = 0.75) were not significantly different between groups. However, after adjustment for confounders, LOS (4.7 vs. 5.8 days, p = 0.027) was significantly shorter and IBD-related surgery (3.5% vs. 7.2%, p = 0.048) was reduced for those receiving corticosteroids early. On subgroup analysis, these findings remained significant only for patients with CD and not UC.Conclusions: For patients admitted with IBD flares without associated abscess, there was an increased LOS and increased risk for IBD-related surgery if corticosteroid therapy was delayed > 12 h after arrival. Guidelines recommend treating acute flares without delay, but guidance on specifics of timing is absent. Our data suggests that treatment should be started within 12 h of presentation, particularly for those with CD.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Anti-TNF Monoclonal Antibody on Enteric Neurons and Enteric Glial Cells in Experimental Colitis.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08872-9

Roberta Figueiroa Souza, Felipe Alexandre Machado, Marcos Antônio Ferreira Caetano, Caroline Bures De Paulo, Patricia Castelucci

{"title":"Effect of Anti-TNF Monoclonal Antibody on Enteric Neurons and Enteric Glial Cells in Experimental Colitis.","authors":"Roberta Figueiroa Souza, Felipe Alexandre Machado, Marcos Antônio Ferreira Caetano, Caroline Bures De Paulo, Patricia Castelucci","doi":"10.1007/s10620-025-08872-9","DOIUrl":"https://doi.org/10.1007/s10620-025-08872-9","url":null,"abstract":"Background: Inflammatory bowel diseases (IBD) affect both enteric neurons and enteric glia, with tumor necrosis factor-alpha (TNF-α) playing a role as an inflammatory mediator.Aims: Analyze the effects of the anti-TNF monoclonal antibody on the myenteric plexus in an experimental model of colitis.Methods: C57BL/6 mice received 3% dextran sodium sulfate (DSS) in drinking water for 7 days in both the DSS and DSS + ADA groups. The Sham group received water. The DSS + ADA group received ADA anti-TNF-α on day 2 of DSS intake. The ADA group was given water throughout the period and received an anti-TNF-α injection on day 2. The study evaluated the number of neurons per ganglion, and the area of the neuronal nitric oxide synthase (nNOS), choline acetyltransferase (ChAT), pan-neuronal marker (PGP9.5), and tumor necrosis factor receptor 2 (TNFR2) immunoreactive (-ir). Double labeling of PGP9.5 with an enteric glial marker (GFAP) was also performed.Results: DSS successfully induced experimental colitis (EC). TNFR2 was detected in the myenteric neurons in all groups. EC affected the enteric neurons, showing a decrease in the number of TNFR2-ir, ChAT-ir, nNOS-ir, and PGP9.5-ir neurons, whereas enteric glial cells increased in both the DSS and DSS + ADA groups. The DSS + ADA group showed number of nNOS-ir, ChAT-ir, and PGP9.5-ir neurons per ganglion similar to Sham group. EC also affected the neuronal profile, resulting in smaller areas in the DSS and DSS + ADA groups.Conclusion: Myenteric neurons are immunoreactive to the TNFR2. DSS altered the myenteric plexus, and anti-TNF monoclonal antibody treatment proved effective against EC due to preventing the pathology from developing.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benign Rectal Schwannoma: A Rare Cause of Increased Fluorodeoxyglucose Uptake.

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-02-13 DOI: 10.1007/s10620-025-08869-4

Tomoya Ueda, Minoru Kato, Ryoji Takada, Toshinori Sueda

引用次数: 0